Cytomegalovirus (CMV) pneumonia is uncommon in patients who have intact immune
systems other than as an occasional complication of cardiopulmonary bypass [1]. Most …

JM Iwasenko, GM Scott, Z. Naing, AR Glanville, WD Rawlinson. Diversity of antiviral‐
resistant human cytomegalovirus in heart and lung transplant recipients. Transpl Infect Dis …

Cytomegalovirus (CMV) is the most common viral pathogen in organ transplant recipients.
The patients at highest risk of developing CMV disease are seronegative recipients of …

Abstract Treatment of cytomegalovirus (CMV) disease in transplant patients is challenging
and, with antiviral resistance to first‐line drugs, it remains uncertain which treatment …

The occurrence of cytomegalovirus infection after solid organ transplantation has been
correlated with decreased patient and allograft survival. The disease has not been …

Cytomegalovirus (CMV) continues to be a cause of substantial morbidity and death after
solid-organ transplantation. There are 3 major consequences of CMV infection: CMV …

The natural history of cytomegalovirus (CMV) disease associated with solid organ
transplantation has been modified as a result of the widespread use of antiviral prophylaxis …

Experience with ganciclovir treatment of life-or sight-threatening cytomegalovirus (CMV)
infections in 22 heart and heart-lung transplant recipients at six medical centers was …

Background Cytomegalovirus is an important cause of morbidity and mortality risk after lung
transplantation. Ganciclovir, when given for a period of up to 3 months after lung …

Cytomegalovirus continues to be one of the most clinically significant infections after solid
organ transplantation. Classic definitions of patients at high risk for infection and tissue …